Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036692714> ?p ?o ?g. }
- W3036692714 endingPage "1397" @default.
- W3036692714 startingPage "1377" @default.
- W3036692714 abstract "From the time of first characterization of PI3K as a heterodimer made up of a p110 catalytic subunit and a regulatory subunit, a wealth of evidence have placed the class IA PI3Ks at the forefront of drug development for the treatment of various diseases including cancer. The p110α isoform was quickly brought at the centre of attention in the field of cancer research by the discovery of cancer-specific gain-of-function mutations in PIK3CA gene in a range of human solid tumours. In contrast, p110δ PI3K was placed into the spotlight of immunity, inflammation and haematologic malignancies because of the preferential expression of this isoform in leucocytes and the rare mutations in PIK3CD gene. The last decade, however, several studies have provided evidence showing that the correlation between the PIK3CA mutations and the response to PI3K inhibition is less clear than originally considered, whereas concurrently an unexpected role of p110δ PI3K in solid tumours has being emerging. While PIK3CD is mostly non-mutated in cancer, the expression levels of p110δ protein seem to act as an intrinsic cancer-causing driver in various solid tumours including breast, prostate, colorectal and liver cancer, Merkel-Cell carcinoma, glioblastoma and neurobalstoma. Furthermore, p110δ selective inhibitors are being studied as potential single agent treatments or as combination partners in attempt to improve cancer immunotherapy, with both strategies to shown great promise for the treatment of several solid tumours. In this review, we discuss the evidence implicating the p110δ PI3K in human solid tumours, their impact on the current state of the field and the potential of using p110δ-selective inhibitors as monotherapy or combined therapy in different cancer contexts." @default.
- W3036692714 created "2020-06-25" @default.
- W3036692714 creator A5031903688 @default.
- W3036692714 creator A5087730270 @default.
- W3036692714 date "2020-06-01" @default.
- W3036692714 modified "2023-10-04" @default.
- W3036692714 title "p110δ PI3K as a therapeutic target of solid tumours" @default.
- W3036692714 cites W1525326448 @default.
- W3036692714 cites W1525343967 @default.
- W3036692714 cites W1541596409 @default.
- W3036692714 cites W1542117945 @default.
- W3036692714 cites W1545503281 @default.
- W3036692714 cites W1546742771 @default.
- W3036692714 cites W1552927675 @default.
- W3036692714 cites W1560571961 @default.
- W3036692714 cites W1568317937 @default.
- W3036692714 cites W1582699368 @default.
- W3036692714 cites W1605118942 @default.
- W3036692714 cites W1658093144 @default.
- W3036692714 cites W1788833617 @default.
- W3036692714 cites W1817905332 @default.
- W3036692714 cites W1838131144 @default.
- W3036692714 cites W1856121658 @default.
- W3036692714 cites W1867136150 @default.
- W3036692714 cites W1896937632 @default.
- W3036692714 cites W1910012553 @default.
- W3036692714 cites W1917614082 @default.
- W3036692714 cites W1922412259 @default.
- W3036692714 cites W1933401810 @default.
- W3036692714 cites W1964841658 @default.
- W3036692714 cites W1965380456 @default.
- W3036692714 cites W1967224800 @default.
- W3036692714 cites W1967690338 @default.
- W3036692714 cites W1968728160 @default.
- W3036692714 cites W1969057487 @default.
- W3036692714 cites W1971052438 @default.
- W3036692714 cites W1971208896 @default.
- W3036692714 cites W1971333358 @default.
- W3036692714 cites W1971620413 @default.
- W3036692714 cites W1975642651 @default.
- W3036692714 cites W1976522626 @default.
- W3036692714 cites W1976910093 @default.
- W3036692714 cites W1977701732 @default.
- W3036692714 cites W1977905203 @default.
- W3036692714 cites W1980040544 @default.
- W3036692714 cites W1980252171 @default.
- W3036692714 cites W1980485314 @default.
- W3036692714 cites W1980547319 @default.
- W3036692714 cites W1982141282 @default.
- W3036692714 cites W1982488143 @default.
- W3036692714 cites W1982935553 @default.
- W3036692714 cites W1983276056 @default.
- W3036692714 cites W1983344122 @default.
- W3036692714 cites W1984198270 @default.
- W3036692714 cites W1985842890 @default.
- W3036692714 cites W1986694073 @default.
- W3036692714 cites W1988835053 @default.
- W3036692714 cites W1991276398 @default.
- W3036692714 cites W1991761103 @default.
- W3036692714 cites W1994957003 @default.
- W3036692714 cites W1995115263 @default.
- W3036692714 cites W1997944395 @default.
- W3036692714 cites W1998038367 @default.
- W3036692714 cites W2000217512 @default.
- W3036692714 cites W2000725338 @default.
- W3036692714 cites W2002112377 @default.
- W3036692714 cites W2002387731 @default.
- W3036692714 cites W2005855615 @default.
- W3036692714 cites W2007444707 @default.
- W3036692714 cites W2009886463 @default.
- W3036692714 cites W2010747804 @default.
- W3036692714 cites W2010784970 @default.
- W3036692714 cites W2012438883 @default.
- W3036692714 cites W2013043293 @default.
- W3036692714 cites W2014186158 @default.
- W3036692714 cites W2015665561 @default.
- W3036692714 cites W2016732129 @default.
- W3036692714 cites W2017190378 @default.
- W3036692714 cites W2017499074 @default.
- W3036692714 cites W2020684181 @default.
- W3036692714 cites W2023075736 @default.
- W3036692714 cites W2024676945 @default.
- W3036692714 cites W2025183726 @default.
- W3036692714 cites W2026861011 @default.
- W3036692714 cites W2026878412 @default.
- W3036692714 cites W2026928416 @default.
- W3036692714 cites W2027239007 @default.
- W3036692714 cites W2027345033 @default.
- W3036692714 cites W2029066126 @default.
- W3036692714 cites W2032166347 @default.
- W3036692714 cites W2032784006 @default.
- W3036692714 cites W2033805603 @default.
- W3036692714 cites W2035016671 @default.
- W3036692714 cites W2036958461 @default.
- W3036692714 cites W2037038519 @default.
- W3036692714 cites W2037239040 @default.
- W3036692714 cites W2037489902 @default.
- W3036692714 cites W2039123767 @default.